Physician profile
Amanda Trang
NPI 1801154810
$10,525.66
in general payments reported to CMS, 2019-2025
26 companies · $1,080 in 2025
The $1,080 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,047 · 2020: $886 · 2021: $1,502 · 2022: $1,314 · 2023: $2,503 · 2024: $1,193 · 2025: $1,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,776.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $7,206.37 | 2019-2025 | Advisor, Aveir, Gallant |
| Abiomed | $556.19 | 2021-2025 | Impella |
| Boston Scientific Corporation | $435.36 | 2019-2025 | Watchman Flx |
| Amgen INC. | $374.23 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $266.23 | 2019-2025 | |
| Kestra Medical Technology Services, INC. | $232.39 | 2025 | Assure Wcd |
| Medtronic, INC. | $229.75 | 2023-2025 | Turbohawk, Symplicity G3, Micra |
| Cvrx, INC. | $226.47 | 2021-2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $201.41 | 2021-2025 | Lifevest |
| Edwards Lifesciences Corporation | $149.61 | 2019 | |
| Janssen Pharmaceuticals, INC | $128.06 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.16 | 2023-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $83.94 | 2022-2025 | Camzyos, Eliquis |
| Osprey Medical INC | $42.00 | 2019 | |
| Scpharmaceuticals INC. | $40.99 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $38.65 | 2024-2025 | Farxiga, Lokelma |
| Kiniksa Pharmaceuticals International, Plc | $32.57 | 2024 | Arcalyst |
| Pfizer INC. | $31.99 | 2023-2025 | |
| Inari Medical, INC. | $27.37 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Novo Nordisk INC | $22.72 | 2024 | Wegovy |
| Tactile Systems Technology INC | $18.82 | 2024 | Entre Plus, Flexitouch Plus |
| Medtronic Vascular, INC. | $18.41 | 2020 | |
| Inspire Medical Systems, INC. | $18.22 | 2024 | Inspire |
| Lexicon Pharmaceuticals, INC. | $18.05 | 2024 | |
| Chiesi USA, INC. | $17.59 | 2025 | Kengreal |
| Merck Sharp & Dohme LLC | $16.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Trang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.